To compare the antiproliferative effects between bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), and mitomycin C in human Tenon's capsule fibroblasts.

Primarily cultured human Tenon's capsule fibroblasts were exposed to 0, 25, 50, 100, and 200 µg/ml bevacizumab and mitomycin C, and incubated for 5 days. Cellular survival and production of nitric oxide were assessed by MTT assay and Griess assay, respectively.

Bevacizumab showed antiproliferative effects only at high concentrations (200 µg/ml) and revealed much less effect on the cellular survival compared to mitomycin C. In addition, bevacizumab did not affect the production of nitric oxide.

The antiproliferative effect of bevacizumab is much lower than mitomycin C in human Tenon's capsule fibroblasts.